Can a modified herpes virus fight recurrent brain tumors?

NCT ID NCT05235074

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This trial is testing an experimental treatment called OH2, a modified herpes simplex virus, for people with recurrent central nervous system tumors, including glioblastoma. The virus is injected into the tumor cavity after surgery to see if it can safely attack cancer cells and slow tumor growth. The study involves two phases: first to find the safest dose, then to evaluate how well it works. Participants are adults with confirmed recurrent brain tumors who have had surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
OH2 injection, an oncolytic type 2 herpes simplex virus
What this could lead to
If successful, this approach could offer a new treatment option for recurrent brain tumors, potentially slowing disease progression and extending survival.
What could go wrong
This is an early-phase trial with a small number of participants, so the benefits are uncertain. There are risks of side effects from the virus, and the treatment may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CENTRAL NERVOUS SYSTEM TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Beijing Tiantan Hospital, Capital Medical University

    Beijing, Beijing Municipality, 100070, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.